Entering text into the input field will update the search result below

European Ad Comm backs expanded use of Biogen's Tysabri in RRMS patients

May 31, 2016 9:05 AM ETBiogen Inc. (BIIB) StockBIIBBy: Douglas W. House, SA News Editor1 Comment
  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval of Biogen's (NASDAQ:BIIB) TYSABRI (natalizumab) for use as disease modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) patients with highly active disease activity despite a full and adequate course of treatment with at least one DMT.
  • The data supporting the company's application, called a type-II variation, was generated in a 10-year prospective real-study study called TOP (TYSABRI Observational Program).
  • A final decision from the European Commission usually takes ~60 days.

Recommended For You

About BIIB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BIIB--
Biogen Inc.